Ruth Adams
Chief Tech/Sci/R&D Officer presso NUVALENT, INC.
Profilo
Ruth Adams is currently working as the Vice President-Clinical Operations at Nuvalent, Inc. Prior to this, she worked as the Head-Clinical Operation at Vigeo Therapeutics, Inc. Ms. Adams completed her undergraduate degree from The University of Southampton.
Posizioni attive di Ruth Adams
| Società | Posizione | Inizio |
|---|---|---|
| NUVALENT, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Precedenti posizioni note di Ruth Adams
| Società | Posizione | Fine |
|---|---|---|
Vigeo Therapeutics, Inc.
 Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Formazione di Ruth Adams
| The University of Southampton | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NUVALENT, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Ruth Adams
